- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Eli Lilly and NRAS Launch Film for RA Awareness Week
Eli Lilly and Company and the National Rheumatoid Arthritis Society (NRAS) announced the launch of a new film, called Behind the Smile. The film encourages people living with rheumatoid arthritis (RA) to have an open conversation with their doctor or nurse about how they are really feeling, and how their disease impacts their day-to-day life.
Eli Lilly and Company and the National Rheumatoid Arthritis Society (NRAS) announced the launch of a new film-Behind the Smile. The film encourages people with rheumatoid arthritis (RA) to speak openly with their doctor or nurse about how they really feel and how their disease effects their daily life.
In conjunction with RA Awareness Week (June 19-25), the film’s goal is to increase awareness of physical and emotional struggles that people with RA deal with every day, and encourage healthcare professionals to listen to what really matters to the individual patient.
Behind the Smile is launched to coincide with the results from the new survey by Lilly, RA Matters, which reveals a lack of understanding about the true impact of RA. To view the film, visit http://www.nras.org.uk/behindthesmile.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
